Cindy is passionate about innovation to make multiomic technologies easier and cheaper to measure.  Such advances are essential to lower barriers to implement scalable, reproducible discoveries that can be translated to the clinic to drive individualized medicine and health equity.  In over 14 years at Illumina and together with customers, she helped develop solutions to better understand genetic risk in diverse populations and holds several Excellence in Technology Transfer awards for her work leading Illumina’s Consortia Program.  She joined Olink in 2020 soon after the launch of the Explore Platform that leverages NGS as a high throughput proteomic readout.  At Olink, she drives population health initiatives, working closely with the UK Biobank, FinnGen, SCALLOP and other large cohort studies.